← SVN001
What podcasts say about SVN001
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about SVN001
2 statements · 2 positive
EU trial data could improve SVN001’s probability of EU marketing approval.
“what our hope would be that if we have EU data in the trial, it would increase the probability of an accepted marketing authorization or marketing approval in certain EU countries in due course.”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 3:59
Adding EU data would significantly increase SVN001’s strategic optionality.
“by potentially adding in EU data, we increase the, let's just call it optionality for that program, I believe, significantly.”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 6:38
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.